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C
ells must follow a strict plan to ac-
complish successful cell division. 
For most cells, deviations from 
this plan, like the presence of extra centro-
somes or chromosomes, can cause real 
trouble: cell death, or possibly cancer.
But not everything in life follows a 
plan. For example, David Pellman says he 
didn’t have any intention to pursue a career 
in research. In college, he’d decided to go 
to medical school, but an early taste of 
research success during a summer project 
in Hidesaburo Hanafusa’s lab (1) sparked 
an interest in basic science. So, after com-
pleting his medical residency, Pellman 
took a postdoctoral position in Gerald 
Fink’s lab at the Massachusetts Institute of 
Technology (2), where he learned to lever-
age yeast genetics to explore the mechan-
ics of cell division. Now, Pellman’s lab at 
the Dana-Farber Cancer Institute is defi  n-
ing how cellular geometry and the scaling 
of protein concentrations place constraints 
on dividing cells (3–6). In the process, 
they’ve gained important insights into the 
cellular conditions that accompany devia-
tions from the usual plan for cell division, 
such as those associated with genome 
doubling and polyploidy.
NOT ACCORDING TO PLAN
You’re trained as an MD?
That’s right. I’m not ac-
tively taking care of pa-
tients now, but I did until 
six or seven years ago. I 
did my internship and resi-
dency at Children’s Hospi-
tal in Boston, and I joined 
the fellowship program at 
Dana-Farber and Children’s 
Hospital, which has a heavy 
scientifi  c emphasis. I had already devel-
oped an interest in research before I arrived, 
and the people there really encouraged 
me to pursue that interest. Eventually I 
chose to become a cell biologist and focus 
primarily on research, but that certainly 
wasn’t my plan at fi  rst.
What was your plan?
I wasn’t the kid who tinkered in the base-
ment with toy chemistry sets. My problem 
was that I was interested in everything. 
When I started college, I didn’t really know 
what I wanted to do.
I actually took a year off during col-
lege and worked with a violin maker, 
learning how to build and repair various 
wooden instruments. I played the guitar 
and thought it would be fun to work with 
something I enjoyed, but I discovered that 
I liked playing the instruments more than 
I liked making them. I still play guitar, but 
mostly just at home with my eight-year-
old son, who plays the piano.
That year off in college really helped 
me to focus; I discovered the difference 
between an avocation and a vocation. 
When I got back to college after my year 
off, I decided to go to medical school.
What got you interested in research?
I had a very lucky experience as an un-
dergraduate. Toward the end of college, I 
took a graduate course in biochemistry 
from Nick Cozzarelli that I really liked, 
and that got me interested in the idea of 
doing research. I was headed back to 
New York, where I grew up, to spend the 
summer with my family before starting 
medical school. I asked 
Nick to recommend some 
labs there, and he suggest-
ed Hidesaburo Hanafusa’s 
lab. I worked there for the 
summer on the localization 
of the viral oncogene Src, 
and things went really well. 
I think I actually got a false 
sense of how science goes 
because our progress was 
so rapid. I wish all starting students could 
have that initial taste of success.
SKETCH THE APPROACH
Your postdoc took you down a different 
road, though?
Yes. I was still interested in cancer, but I 
was also attracted to the idea of drilling 
down and fi  guring out how the signaling 
pathways involved in transformation 
worked. At the time there was very little 
information about how signaling path-
ways operated, and very little ability to 
manipulate those pathways in mammalian 
cells. On the other hand, yeast was a very 
attractive system, because I could use 
genetics to study individual pathways.
While it’s obviously not possible to 
study cancer in yeast, you can use them to 
understand how normal cell biological pro-
cesses work. As my postdoc developed I 
decided I was going to focus on mitosis 
and cell division, and since then I haven’t 
looked back. I basically thought that if I 
was really going to understand abnormal 
chromosome segregation in cancer, I had 
to fi  rst understand as much as I could about 
normal cell division mechanisms.
When you started your own lab at Dana-
Farber, what questions did you tackle?
When I was a postdoc, Gerry was always 
telling me, “All you need is a good mu-
tant.” Easier said than done. One can get 
mutants of various sorts, but finding the 
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informative ones can be tricky. One of the 
fi  rst things we did in my own lab was a 
genetic screen to try to identify new spin-
dle components. This uncovered a number 
of genes involved in spindle positioning 
and asymmetric cell division, and perhaps 
the most interesting was a mutation in a 
formin gene. When we followed up on that 
mutant, we quickly found that formins 
assemble actin structures that form tracts 
for the polarized transport necessary for 
building the daughter cell, including the 
astral microtubules that orient the spindle 
during asymmetric division.
SCHEMATICS OF CELL DIVISION
How have your interests evolved since?
At one point we were studying a conserved 
microtubule regulator that in yeast is called 
Bik1 and in higher cells is called Clip-170. 
We thought Bik1 had an important role in 
kinetochore microtubule dynamics and 
kinetochore-microtubule attachments, so we 
were disappointed to fi  nd that lack of Bik1 
doesn’t cause striking phenotypes—the 
yeast are basically fi  ne. Then we noticed that 
although the Bik1 gene isn’t essential in hap-
loid or diploid cells, it’s absolutely required 
in triploid or tetraploid cells. We called this 
phenomenon ploidy-specifi   c lethality, and 
it’s opened up a lot of questions for us.
For example, genome doublings hap-
pen frequently in evolution, and it’s still 
somewhat debated whether they are simply 
accidents that become fi  xed or if they’re real 
drivers of evolutionary diversity. The fact 
that ploidy-specifi  c lethality exists suggests 
that the genetic requirements are different 
in genome-doubled versus normal cells. 
Clearly, there are lots of detrimental aspects 
to genome doubling, but we’d like to under-
stand whether there are any advantages to it, 
and if there are any selective pressures for it. 
Along with that, we’d like to understand 
how genome doubling or aneuploidy affect 
cell physiology. There may be a translational 
angle to this if we can fi  nd ways to specifi  -
cally kill aneuploid cells—a prominent fea-
ture of most cancers.
Is there a link between genome doubling 
and cancer?
Genome doubling can occur through a fail-
ure of cytokinesis, which creates tetraploid 
cells. In 2005 we published 
a paper showing that cytoki-
nesis failure can promote 
tumorigenesis in a mouse 
breast cancer model. One of 
the things that we observed 
in that paper was that tetra-
ploid-derived tumors are 
genetically unstable, a feature that is shared, 
at least in part, with tetraploid yeast. Of 
course, many natural tumors are also 
genetically unstable; they frequently lose or 
gain entire chromosomes—a phenomenon 
known as chromosomal instability (CIN). 
While the signifi  cance of CIN is complex 
and still debated—it’s unclear whether it 
drives the cancer or if it’s just something the 
cancer cells have to put up with—the causes 
of CIN are much easier to tackle. We can 
ask, is there a genetic origin for CIN?
There’s an idea that goes all the way 
back to Theodor Boveri’s famous mono-
graph where he suggested that aneuploidy, 
usually accompanied by centrosome ampli-
fi  cation, might somehow cause cancer. He 
further recognized that cytokinesis failure 
would be a simple way to generate centro-
some amplifi  cation. Based on this early 
work, it was thought that extra centrosomes 
might drive CIN through the formation of 
multipolar cell divisions—fragmentation 
of cells into highly aneuploid progeny. 
So, Neil Ganem in my lab imaged more 
than 10,000 cell divisions in various CIN 
cancer cells, looking for multipolar cell di-
visions. But he found that multipolar cell 
division almost never happened and, if it 
did, it almost always led to unviable cells. 
Instead, consistent with previous work, we 
found that extra centrosomes are ultimately 
bundled into bipolar spindles, but before 
they are bundled, they pass through a multi-
polar geometry. This time spent in a multi-
polar geometry sets up abnormal attach-
ments between kinetochores and spindle 
microtubules, which in turn causes un-
equal distribution of chromosomes to 
daughter cells. So, there is a trade-off: 
the clustering process allows cells to sur-
vive, but the cost is CIN. There may or may 
not be dedicated CIN genes, but oncogenic 
mutations that give rise to extra centrosomes 
can cause geometric problems in spindle as-
sembly that might be a com-
mon cause of CIN.
This raises all sorts of inter-
esting questions concerning 
how cells scale geometric 
structures and metabolic net-
works. There are many tissues 
in the body where polyploidy 
is actually part of the normal developmen-
tal program. We’d really like to understand 
how and why polyploidy normally comes 
about, and that’s one question we’ll be 
working on next.
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Extra centrosomes (yellow) pass through 
abnormal geometries, causing spindle 
microtubules (green) to form abnormal 
attachments to kinetochores (red) and 
chromosomes (white).
“We can ask, 
is there a 
genetic origin 
for CIN?”
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